Adage Capital Partners
BDTX icon

Adage Capital Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Adage Capital Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-233,000
Closed -$7.47M – 963
2020
Q4 		$7.47M Buy
233,000
+88,000
+61% +$2.89M 0.02% 638
2020
Q3 		$4.38M Buy
+145,000
New +$4.41M 0.01% 653

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Adage Capital Partners's BDTX Position: Q1 2021 in Review

Adage Capital Partners sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 233,000 shares — an estimated $7.47M sold.

Adage Capital Partners first reported a position in BDTX in Q3 2020 and held it in 2 quarters. The position peaked at $7.47M in Q4 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

  • Adage Capital Partners reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Adage Capital Partners sold 233,000 Black Diamond Therapeutics shares in Q1 2021, an estimated $7.47M.
  • Adage Capital Partners first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 2 quarters.
  • Adage Capital Partners's Black Diamond Therapeutics position peaked at $7.47M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.